Treatment Modification Based on Early Assessment of CML Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2020

Conditions
CML
Interventions
OTHER

Treatment modification based on molecular response at 3 months

Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI

Trial Locations (1)

49100

RECRUITING

Rabin Medical Center, Petah Tikva

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Rambam Health Care Campus

OTHER

collaborator

Wolfson Medical Center

OTHER_GOV

collaborator

Bnai Zion Medical Center

OTHER_GOV

collaborator

HaEmek Medical Center, Israel

OTHER

collaborator

Hadassah Medical Organization

OTHER

lead

Rabin Medical Center

OTHER